Orchid to Webcast Presentation at Thomas Weisel Partners' Healthcare Tailwinds Conference

Apr 02, 2001, 01:00 ET from Orchid BioSciences, Inc.

    PRINCETON, N.J., April 2 /PRNewswire/ --
 Orchid BioSciences, Inc. (Nasdaq: ORCH), a leading provider of products,
 services and technologies for SNP scoring and genetic diversity analyses,
 today announced that Dr. Dale Pfost, chairman, president and chief executive
 officer of Orchid, is scheduled to present at the Thomas Weisel Partners'
 Healthcare Tailwinds Conference.
     The presentation will take place on Tuesday, April 3, 2001 at 8:00 a.m. PT
 (11:00 a.m. ET) at The Ritz-Carlton Hotel in San Francisco, CA.
     In the presentation, Dr. Pfost will provide an overview of Orchid's
 multi-faceted business model, an update on how the company is progressing each
 element of Orchid's business, and a summary of other recent developments. The
 presentation will be broadcast live via the Internet and can be accessed at:
 http://www.veracast.com/twp_healthcare_2001/webcasts/48202309.cfm
     Following the live presentation, the Webcast will be archived for 30 days
 and can be accessed at the above referenced address.
 
     Orchid BioSciences, Inc. is a leading provider of products, services and
 technologies for SNP scoring and genetic diversity analyses.  Orchid has
 developed SNP-IT(TM), its proprietary SNP analysis technology, and markets
 SNPstream(R) instruments and SNPware(TM) consumables that rapidly generate
 highly accurate, cost effective SNP information. SNP-IT is usable in
 environments ranging from small-scale laboratories to large commercial
 facilities.  Its versatility is enabling Orchid to partner with industry
 leaders to make SNP-IT-enabled products available on a wide variety of
 instrument platforms as part of Orchid's Platform Propagation Strategy(TM).
 Orchid provides high throughput SNP scoring services to pharmaceutical,
 biotechnology and academic customers through its MegaSNPatron(TM) facilities,
 and DNA testing through its GeneScreen and Cellmark businesses that conduct
 paternity and forensics testing, as well as clinical quality genotyping.
 Orchid also provides content-rich SNP databases and SNP panels to its
 customers and collaborators.  Through its Pharmaceutical Value Creation
 business, Orchid seeks to identify and patent proprietary medical applications
 of SNPs. More information on Orchid can be found at its web site
 http://www.orchid.com.
 
     Contact:  Orchid BioSciences, Inc.
               609-750-2296
               Barbara L. Lindheim
               Vice President, Strategic Communications
 
 

SOURCE Orchid BioSciences, Inc.
    PRINCETON, N.J., April 2 /PRNewswire/ --
 Orchid BioSciences, Inc. (Nasdaq: ORCH), a leading provider of products,
 services and technologies for SNP scoring and genetic diversity analyses,
 today announced that Dr. Dale Pfost, chairman, president and chief executive
 officer of Orchid, is scheduled to present at the Thomas Weisel Partners'
 Healthcare Tailwinds Conference.
     The presentation will take place on Tuesday, April 3, 2001 at 8:00 a.m. PT
 (11:00 a.m. ET) at The Ritz-Carlton Hotel in San Francisco, CA.
     In the presentation, Dr. Pfost will provide an overview of Orchid's
 multi-faceted business model, an update on how the company is progressing each
 element of Orchid's business, and a summary of other recent developments. The
 presentation will be broadcast live via the Internet and can be accessed at:
 http://www.veracast.com/twp_healthcare_2001/webcasts/48202309.cfm
     Following the live presentation, the Webcast will be archived for 30 days
 and can be accessed at the above referenced address.
 
     Orchid BioSciences, Inc. is a leading provider of products, services and
 technologies for SNP scoring and genetic diversity analyses.  Orchid has
 developed SNP-IT(TM), its proprietary SNP analysis technology, and markets
 SNPstream(R) instruments and SNPware(TM) consumables that rapidly generate
 highly accurate, cost effective SNP information. SNP-IT is usable in
 environments ranging from small-scale laboratories to large commercial
 facilities.  Its versatility is enabling Orchid to partner with industry
 leaders to make SNP-IT-enabled products available on a wide variety of
 instrument platforms as part of Orchid's Platform Propagation Strategy(TM).
 Orchid provides high throughput SNP scoring services to pharmaceutical,
 biotechnology and academic customers through its MegaSNPatron(TM) facilities,
 and DNA testing through its GeneScreen and Cellmark businesses that conduct
 paternity and forensics testing, as well as clinical quality genotyping.
 Orchid also provides content-rich SNP databases and SNP panels to its
 customers and collaborators.  Through its Pharmaceutical Value Creation
 business, Orchid seeks to identify and patent proprietary medical applications
 of SNPs. More information on Orchid can be found at its web site
 http://www.orchid.com.
 
     Contact:  Orchid BioSciences, Inc.
               609-750-2296
               Barbara L. Lindheim
               Vice President, Strategic Communications
 
 SOURCE  Orchid BioSciences, Inc.